Focused On-demand Library for Importin-9

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96P70

UPID:

IPO9_HUMAN

Alternative names:

Ran-binding protein 9

Alternative UPACC:

Q96P70; B1ASV5; Q8N1Y1; Q8N3I2; Q8NCG9; Q96SU6; Q9NW01; Q9P0A8; Q9ULM8

Background:

Importin-9, also known as Ran-binding protein 9, plays a crucial role in nuclear transport, mediating the import of proteins like histones and proteasome into the nucleus. It functions as a receptor for nuclear localization signals, facilitating the docking of importin/substrate complexes to the nuclear pore complex. This process is powered by a Ran-dependent mechanism, ensuring the directional transport of molecules between the cytoplasm and nucleus.

Therapeutic significance:

Understanding the role of Importin-9 could open doors to potential therapeutic strategies. Its involvement in the nuclear import of critical proteins highlights its importance in cellular function and the potential impact on disease treatment through targeted modulation.